Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

Abstract excerpt

CONTEXT: Activating RET alterations have been reported in a variety of solid tumors, including pheochromocytoma where they occur both sporadically and as part of familial multiple endocrine neoplasia type 2 (MEN2) syndromes. Selpercatinib is a first-in-class, highly selective, and potent small molecule RET kinase inhibitor that has demonstrated marked and durable antitumor activity in diverse RET-activated solid...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adrenal Gland Neoplasms
• Share to Clinical Trials, Phase I as Topic